Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Completed
Novartis Pharmaceuticals
Phase 3
2014-07-18
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the
reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF
with preserved ejection fraction.
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
Completed
Novartis Pharmaceuticals
Phase 4
2016-04-29
The purpose of this study was to assess the effect of in-hospital initiation of
sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP
in patients who have been stabilized following hospitalization for acute decompensated heart
failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤
40%).
Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
Terminated
American Heart Association
Phase 2
2017-12-31
This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain
free walking duration on patients with peripheral arterial disease, a condition caused by
decreased blood flow to the muscles in the legs.
Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
Terminated
University of Minnesota
Phase 2
2017-12-31
This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain
free walking duration on patients with peripheral arterial disease, a condition caused by
decreased blood flow to the muscles in the legs.
Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
Terminated
University of Minnesota - Clinical and Translational Science Institute
Phase 2
2017-12-31
This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain
free walking duration on patients with peripheral arterial disease, a condition caused by
decreased blood flow to the muscles in the legs.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
